Firms join in new IMI adaptive pathways project
This article was originally published in Scrip
The EU's Innovative Medicines Initiative (IMI) is about to launch a new collaborative public-private project looking at how best to co-ordinate and support activities being conducted in the area of adaptive pathways, with a view to producing a comprehensive plan for developing and using relevant tools and methodologies throughout the product life cycle.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.